These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15105795)

  • 41. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo.
    Poindexter A; Reape KZ; Hait H
    Contraception; 2008 Aug; 78(2):113-9. PubMed ID: 18672111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral contraceptives and venous thromboembolism: consensus conference statement.
    Dialogues in Contraception Consensus Conference (1995: Chicago)
    Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trends in oral contraceptive development and utilization: looking to the future.
    Contracept Rep; 1997 Jan; 7(5):4-13. PubMed ID: 12320650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Effect of Oral Contraceptive Hormones on Anterior Cruciate Ligament Strength.
    Konopka JA; Hsue L; Chang W; Thio T; Dragoo JL
    Am J Sports Med; 2020 Jan; 48(1):85-92. PubMed ID: 31765227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical study of the low dose oral contraceptive novynette].
    Uchikova E; Milchev N
    Akush Ginekol (Sofiia); 2003; 42(4):15-6. PubMed ID: 14577362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
    Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
    Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol.
    Paoletti AM; Lello S; Fratta S; Orrù M; Ranuzzi F; Sogliano C; Concas A; Biggio G; Melis GB
    Fertil Steril; 2004 Mar; 81(3):645-51. PubMed ID: 15037415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.
    Dore DD; Norman H; Loughlin J; Seeger JD
    Contraception; 2010 May; 81(5):408-13. PubMed ID: 20399947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
    Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    Odlind V; Milsom I; Persson I; Victor A
    Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Oral contraceptives and their minor side effects: comparison of three low-dose estroprogestinic combinations].
    Perrone G; Calzolari E; Mancone M; Masci A; Steffe M; Tesseri E
    Patol Clin Ostet Ginecol; 1987; 15(1):6-11. PubMed ID: 12286707
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
    Blode H; Schürmann R; Benda N
    Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
    Klipping C; Marr J
    Contraception; 2005 Jun; 71(6):409-16. PubMed ID: 15914128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
    White T; Jain JK; Stanczyk FZ
    Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short-term response of bone turnover to low-dose oral contraceptives in exercising women with hypothalamic amenorrhea.
    Vescovi JD; VanHeest JL; De Souza MJ
    Contraception; 2008 Feb; 77(2):97-104. PubMed ID: 18226672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins.
    White T; Ozel B; Jain JK; Stanczyk FZ
    Contraception; 2006 Oct; 74(4):293-6. PubMed ID: 16982228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH; Sudik R
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables.
    Kluft C; Meijer P; LaGuardia KD; Fisher AC
    Contraception; 2008 Feb; 77(2):77-83. PubMed ID: 18226669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.